But for me the big point is: CMS has done something bold and novel – creating what could be a path to getting life-altering but extremely expensive therapies to people who simply wouldn’t be able to get them otherwise. Yes, the unknowns loom large. The biggest: will the counterparties – Medicaid plans and manufacturers – want to play?
read full article ›Thoughts from Roger Longman on Arena Bioworks and new models for creating differentiated innovations for patients and the healthcare system. TLDR: An interesting BUT expensive experiment.
read full article ›Coming out of the overwhelming focus on obesity drugs during the JPMorgan Chase & Co. Healthcare Conference, Eli Lilly and Company and Novo Nordisk have both taken beginning of the year price increases.
read full article ›There was much discussion at hashtag#JPM2024 on the travails of cell therapy companies. Real Endpoints co-founder Roger Longman has been thinking about the challenges and opportunities.
read full article ›JPM 2024 is officially in the books! Panels, presentations, receptions, meetings - always an amazingly inspiring place to connect, learn and share together as an industry with friends, colleagues and clients.
read full article ›Remember that post last week when we predicted that Amazon would do something big in healthcare, since it was tired of being dissed for not going far enough with its health ambitions... Not sure this qualifies but it sure is interesting news for Omada.
read full article ›At the Sachs 7th Neuroscience Innovation Forum, Jeff Berkowitz reporting robust discussion about the twin commercial challenges of reimbursement and physician patient demand.
read full article ›Real Endpoints is excited to be attending the JPMorgan Chase & Co. healthcare conference next week!
read full article ›Macbeth’s three witches weren’t wrong with their predictions. Macbeth just didn’t understand them. Ours are clearer - and a lot less scary.
read full article ›Very excited for our CEO, Jeff Berkowitz to be participating in the Sachs NIF at JPM24. Given the level of innovation in CNS, it's a timely discussion.
read full article ›